Mothaffar Rimawi, MD, on HR-Positive, HER2-Positive Breast Cancer: Results of the NRG Oncology/NSABP B-52 Trial
2016 San Antonio Breast Cancer SymposiumMothaffar Rimawi, MD, of the Smith Breast Center at Baylor College of Medicine, discusses phase II findings from a study evaluating pathologic complete response in patients with HR-positive, HER2-positive disease treated with neoadjuvant docetaxel, carboplatin, trastuzumab, and pertuzumab with or without estrogen deprivation (Abstract S3-06).
Related Videos
Anne Hudson Blaes, MD, on Aromatase Inhibitors and Cardiovascular Disease
Anne Hudson Blaes, MD, of the University of Minnesota, discusses the association between aromatase inhibitors, endothelial function, and early heart disease (Abstract S5-07).
Sonja Vliek, MD, and Sabine Linn, MD, PhD, on Early Breast Cancer: Results of the TEAM IIb Trial
Sabine Linn, MD, PhD, and Sonja Vliek, MD, both of the Netherlands Cancer Institute, discuss study findings on adjuvant ibandronate in postmenopausal women with early...
Ruth O'Regan, MD, on Locally Advanced and Metastatic Breast Cancer: Results of the BELLE-3 Trial
Ruth O'Regan, MD, of the University of Wisconsin, discusses study findings on buparlisib plus fulvestrant in postmenopausal women with HR-positive, HER2-positive, aromatase inhibitor–...
Virginia G. Kaklamani, MD, DSc, on Early Breast Cancer: Year in Review
Virginia G. Kaklamani, MD, DSc, of The University of Texas Health Science Center, discusses new directions in prevention, early detection, and treatment of early-stage breast cancer, ...
Peter Bach, MD, on The Global Cost of Cancer Care
Peter Bach, MD, of Memorial Sloan Kettering Cancer Center, summarizes his plenary lecture on drug costs and their effect on the affordability of cancer care worldwide (Plenary Lecture...
